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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPERInterventional Therapy for Severe Pulmonary Artery Hypertension 611
Paul Bhamra-Ariza, Anne M. Keogh, David W. M. Muller
Despite improvements in medical therapy, the overall prognosis of patients with severe
pulmonary arterial hypertension remains poor. This paper describes both established and
novel percutaneous interventional techniques that may palliate or bridge pulmonary
hypertension patients to transplant. The techniques reviewed include atrial septostomy,
creation of a Pott’s shunt from the pulmonary artery to the descending aorta, angioplasty
of the bronchial arteries, and pulmonary artery denervation.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGYIntraprocedural Stent Thrombosis 619
Philippe Généreux, Gregg W. Stone, Robert A. Harrington, C. Michael Gibson, Ph. Gabriel Steg,
Sorin J. Brener, Dominick J. Angiolillo, Matthew J. Price, Jayne Prats, Laura LaSalle, Tiepu Liu,
Meredith Todd, Simona Skerjanec, Christian W. Hamm, Kenneth W. Mahaffey, Harvey D. White,
Deepak L. Bhatt, for the CHAMPION PHOENIX Investigators
Généreux and colleagues evaluated the clinical impact of intraprocedural stent thrombosis
(IPST). An independent core laboratory blinded to treatment assignment performed a frame-
by-frame angiographic analysis in 10,939 patients undergoing percutaneous coronary
intervention (PCI) randomly assigned to cangrelor or clopidogrel. IPST was deﬁned as new
or worsening thrombus related to stent deployment any time during the procedure. IPST
developed in 35 of 5,470 (0.6%) patients in the cangrelor arm and 54 of 5,469 (1.0%) patients
in the clopidogrel arm (odds ratio: 0.65). IPST was associated with a marked increase in
composite ischemia (ischemia-driven revascularization or new-onset out-of-laboratory stent
thrombosis) at 48 h and at 30 days. The authors conclude that cangrelor substantially reduces
the risk of IPST, which likely contributes to its beneﬁcial effects compared with clopidogrel
at 48 h and 30 days post-PCI.(continued on page A-18)
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Raute Sunder-Plassmann, Petra Jilma-Stohlawetz, Christine Mannhalter, Martin Posch, Bernd Jilma
Hobl and colleagues investigated whether morphine administration affects the
pharmacokinetics and pharmacodynamics of clopidogrel loading dose administration.
Twenty-four healthy subjects received a loading dose of 600 mg clopidogrel together with
placebo or 5 mg morphine intravenously in a randomized, double-blind, placebo-controlled,
cross-over trial. Morphine injection delayed clopidogrel absorption and reduced the area
under the curve levels of its active metabolite by 34%. Morphine delayed the maximal
inhibition of platelet aggregation on average by 2 h. Morphine delays clopidogrel absorption,
decreases plasma levels of clopidogrel active metabolite, and diminishes its effectiveness,
which might lead to treatment failure in susceptible individuals.CARDIOMETABOLIC RISKPulse Wave Velocity Improves CV Risk Prediction 636
Yoav Ben-Shlomo, Melissa Spears, Chris Boustred, Margaret May, Simon G. Anderson,
Emelia J. Benjamin, Pierre Boutouyrie, James Cameron, Chen-Huan Chen, J. Kennedy Cruickshank,
Shih-Jen Hwang, Edward G. Lakatta, Stephane Laurent, João Maldonado, Gary F. Mitchell,
Samer S. Najjar, Anne B. Newman, Mitsuru Ohishi, Bruno Pannier, Telmo Pereira,
Ramachandran S. Vasan, Tomoki Shokawa, Kim Sutton-Tyrell, Francis Verbeke,
Kang-Ling Wang, David J. Webb, Tine Willum Hansen, Sophia Zoungas, Carmel M. McEniery,
John R. Cockcroft, Ian B. Wilkinson
Ben-Shlomo and colleagues performed a systematic review and meta-analysis to determine
whether aortic pulse wave velocity (aPWV) improves prediction of cardiovascular (CV) events
beyond conventional risk factors. Individual participant data from 16 studies were combined,
resulting in 17,635 participants, 10% of whom had a CV event. The pooled age- and
sex-adjusted hazard ratio per SD change in log aPWV was 1.35 for coronary heart disease,
1.54 for stroke, and 1.45 for CV disease. Reclassiﬁcation indexes showed that the addition of
aPWV improved risk prediction. aPWV may enable better identiﬁcation of
high-risk populations who will beneﬁt from more aggressive CV risk factor management.
Editorial Comment: Charalambos Vlachopoulos, Konstantinos Aznaouridis,
Christodoulos Stefanadis, p. 647(continued on page A-19)
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Miklos Z. Molnar, Kamyar Kalantar-Zadeh, Evan H. Lott, Jun Ling Lu, Sandra M. Malakauskas,
Jennie Z. Ma, Darryl L. Quarles, Csaba P. Kovesdy
Molnar and colleagues performed a retrospective chart review of almost 150,000 U.S.
veterans with varying stages of chronic kidney disease (CKD) to assess the association
between use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor
blockers (ARBs) and mortality in CKD patients. ACEI/ARB administration was associated
with a signiﬁcantly lower risk of mortality both in the intention-to-treat analysis and in the
as-treated analysis. The association of ACEI/ARB treatment with lower risk of mortality
was present in all examined subgroups. In this large contemporary cohort of
nondialysis-dependent CKD patients, ACEI/ARB administration was associated with
greater survival.
Editorial Comment: Kevin Damman, Hiddo J. Lambers-Heerspink, p. 659HEART FAILUREReferral Criteria to Heart Failure Centers 661
Tonje Thorvaldsen, Lina Benson, Marcus Ståhlberg, Ulf Dahlström, Magnus Edner, Lars H. Lund
Thorvaldsen and colleagues assessed observed and expected all-cause mortality in 10,062
patients with New York Heart Association (NYHA) functional class III to IV heart failure
(HF) and ejection fraction (EF) <40% registered in the Swedish Heart Failure Registry. Five
pre-speciﬁed universally available risk factors were assessed using multivariable Cox
regression: systolic blood pressure 90 mm Hg, creatinine 160 mmol/l, hemoglobin 120
g/l, no renin-angiotensin system antagonist, and no b-blocker. For patients age 80 years,
the presence of 1, 2, or 3 to 5 of these risk factors conferred an independent hazard ratio for
all-cause mortality of 1.40, 2.30, and 4.07, and a 1-year survival of 79%, 60%, and 39%,
respectively. The authors conclude that for patients age 80 years with NYHA functional
class III to IV HF and EF <40%, mortality is predominantly related to HF or its
comorbidities. Patents with 1 of these risk factors may beneﬁt from either heart transplant/
mechanical assist device or potential palliative care and thus may beneﬁt from referral to an
advanced HF center.(continued on page A-20)
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Isaac R. Whitman, Vickas V. Patel, Elsayed Z. Soliman, David A. Bluemke, Amy Praestgaard,
Aditya Jain, David Herrington, Joao A. C. Lima, Steven M. Kawut
Current electrocardiographic (ECG) criteria for right ventricular hypertrophy (RVH) were
based on cadaveric dissection in small studies. Whitman and colleagues assessed the
diagnostic properties of ECG criteria for RVH measured by cardiac magnetic resonance
imaging (cMRI) in adults without clinical cardiovascular disease. Traditional ECG criteria
were speciﬁc (many >95%) but had low sensitivity for RVH by cMRI. The positive
predictive values were not sufﬁciently high as to be clinically useful (maximum 12%).
Classiﬁcation and regression tree analysis revealed that no combination of ECG variables was
better than the criteria used singly. These results show that the recommended ECG
screening criteria for RVH are not sufﬁciently sensitive or speciﬁc for screening for mild
RVH in adults without clinical cardiovascular disease.PERIPHERAL VASCULAR DISEASEStatin Use Associated With Reduced MACCE in Patients With
Chronic Limb Ischemia682Gregory G. Westin, Ehrin J. Armstrong, Heejung Bang, Khung-Keong Yeo, David Anderson,
David L. Dawson, William C. Pevec, Ezra A. Amsterdam, John R. Laird
While statin medications are recommended for secondary prevention in patients with
peripheral arterial disease (PAD), their effectiveness in patients with chronic limb ischemia
(CLI) is uncertain. Westin and colleagues performed a retrospective chart review of 380 CLI
patients. A total of 65% of patients were prescribed statins. After propensity weighting, statin
therapy was associated with lower 1-year rates of major adverse cardiovascular and
cerebrovascular events (MACCE) (stroke, myocardial infarction, or death) (hazard ratio
[HR]: 0.53), mortality (HR: 0.49), and major amputation or death (HR: 0.53). Statin use
was also associated with improved lesion patency among patients undergoing infrapopliteal
angioplasty. These robust, although nonrandomized, results suggest that there are signiﬁcant
beneﬁts for statin use in patients who present with CLI.
Editorial Comment: Michael R. Jaff, p. 691
